Estimation of antitumor activity of compound T1097 - NOS inhibitor and glycolysis inhibitor - on experimental Erlich carcinoma in vivo
Open Access
- 1 November 2020
- journal article
- research article
- Published by IOP Publishing in Journal of Physics: Conference Series
- Vol. 1701 (1), 012019
- https://doi.org/10.1088/1742-6596/1701/1/012019
Abstract
The antitumor potential of a new original compound T1097 to realize a complex antineoblastic effect - NOS-inhibiting anti-angiogenic and HK2-inhibiting hypoxia-oriented cytotoxic - was investigated on the model of transplantable Ehrlich carcinoma in vivo. During the entire observation period, T1097 showed pronounced dose-dependent antitumor properties: statistically significant inhibitory effect of T1097 on the growth of tumor nodes exceeded the effect of original compound - HK2-inhibitor 3-bromopyruvate in an equimolar dose. The maximum antineoblastic effect (61%) of T1097 was obtained with its subchronic parenteral administration at a dose of 17 mg/kg and was not accompanied by the development of tumor resistance. Our findings confirm the prospects of this direction in the search for new drugs.This publication has 3 references indexed in Scilit:
- Tumor Energy Metabolism and Potential of 3-Bromopyruvate as an Inhibitor of Aerobic Glycolysis: Implications in Tumor TreatmentCancers, 2019
- Modes of resistance to anti-angiogenic therapyNature Reviews Cancer, 2008
- Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinaseCancer Letters, 2001